Cover Image
市場調查報告書

Minoryx Therapeutics s.l.:產品平台分析

Minoryx Therapeutics s.l. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319986
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Minoryx Therapeutics s.l.:產品平台分析 Minoryx Therapeutics s.l. - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 20 Pages
簡介

Minoryx Therapeutics s.l.是致力於危及生命的疾病和罕見疾病的新治療方法及治療藥的開發與製造的製藥公司,著重新的小分子藥物,及穩定不穩定的蛋白質的藥理學性伴護蛋白的開發。該公司的藥理學伴護蛋白使用於遺傳疾病和中樞神經系統疾病的治療上。也進行跟大學和研究機關的共同研究。

本報告提供Minoryx Therapeutics s.l.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Minoryx Therapeutics s.l.的基本資料

  • Minoryx Therapeutics s.l.概要
  • 主要資訊
  • 企業資料

Minoryx Therapeutics s.l. :R&D概要

  • 主要的治療範圍

Minoryx Therapeutics s.l. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Minoryx Therapeutics s.l. :開發中產品概況

  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Minoryx Therapeutics s.l. :藥物簡介

  • pioglitazone hydrochloride
  • Small Molecules for Congenital Disorder of Glycosilation
  • Small Molecules for GM1-gangliosidosis And Morquio B

Minoryx Therapeutics s.l. :開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

Minoryx Therapeutics s.l. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06941CDB

Summary

Global Markets Direct's, 'Minoryx Therapeutics s.l. - Product Pipeline Review - 2015', provides an overview of the Minoryx Therapeutics s.l.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Minoryx Therapeutics s.l.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Minoryx Therapeutics s.l. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Minoryx Therapeutics s.l.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Minoryx Therapeutics s.l.'s pipeline products

Reasons to buy

  • Evaluate Minoryx Therapeutics s.l.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Minoryx Therapeutics s.l. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Minoryx Therapeutics s.l.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Minoryx Therapeutics s.l. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Minoryx Therapeutics s.l.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Minoryx Therapeutics s.l. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Minoryx Therapeutics s.l. Snapshot
    • Minoryx Therapeutics s.l. Overview
    • Key Information
    • Key Facts
  • Minoryx Therapeutics s.l. - Research and Development Overview
    • Key Therapeutic Areas
  • Minoryx Therapeutics s.l. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Minoryx Therapeutics s.l. - Pipeline Products Glance
    • Minoryx Therapeutics s.l. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Minoryx Therapeutics s.l. - Drug Profiles
    • pioglitazone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Congenital Disorder of Glycosilation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for GM1-gangliosidosis And Morquio B
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Minoryx Therapeutics s.l. - Pipeline Analysis
    • Minoryx Therapeutics s.l. - Pipeline Products by Target
    • Minoryx Therapeutics s.l. - Pipeline Products by Molecule Type
    • Minoryx Therapeutics s.l. - Pipeline Products by Mechanism of Action
  • Minoryx Therapeutics s.l. - Recent Pipeline Updates
  • Minoryx Therapeutics s.l. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Minoryx Therapeutics s.l., Key Information
  • Minoryx Therapeutics s.l., Key Facts
  • Minoryx Therapeutics s.l. - Pipeline by Indication, 2015
  • Minoryx Therapeutics s.l. - Pipeline by Stage of Development, 2015
  • Minoryx Therapeutics s.l. - Monotherapy Products in Pipeline, 2015
  • Minoryx Therapeutics s.l. - Preclinical, 2015
  • Minoryx Therapeutics s.l. - Discovery, 2015
  • Minoryx Therapeutics s.l. - Pipeline by Target, 2015
  • Minoryx Therapeutics s.l. - Pipeline by Molecule Type, 2015
  • Minoryx Therapeutics s.l. - Pipeline Products by Mechanism of Action, 2015
  • Minoryx Therapeutics s.l. - Recent Pipeline Updates, 2015

List of Figures

  • Minoryx Therapeutics s.l. - Pipeline by Top 10 Indication, 2015
  • Minoryx Therapeutics s.l. - Pipeline by Stage of Development, 2015
  • Minoryx Therapeutics s.l. - Monotherapy Products in Pipeline, 2015
  • Minoryx Therapeutics s.l. - Pipeline by Top 10 Target, 2015
  • Minoryx Therapeutics s.l. - Pipeline by Top 10 Molecule Type, 2015
Back to Top